Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1960 1
1963 1
1966 1
1976 1
1977 1
1980 1
1982 3
1984 1
1986 1
1988 1
1990 1
1991 2
1994 1
1995 1
1996 5
1997 9
1998 2
1999 4
2000 7
2002 3
2003 9
2004 2
2005 4
2006 1
2007 5
2008 6
2009 7
2010 6
2011 4
2012 9
2013 10
2014 7
2015 2
2016 3
2017 3
2018 3
2019 4
2020 2
2021 3
2023 4
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

132 results

Results by year

Filters applied: . Clear all
Page 1
Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup.
Sperling RA, Jack CR Jr, Black SE, Frosch MP, Greenberg SM, Hyman BT, Scheltens P, Carrillo MC, Thies W, Bednar MM, Black RS, Brashear HR, Grundman M, Siemers ER, Feldman HH, Schindler RJ. Sperling RA, et al. Among authors: grundman m. Alzheimers Dement. 2011 Jul;7(4):367-85. doi: 10.1016/j.jalz.2011.05.2351. Alzheimers Dement. 2011. PMID: 21784348 Free PMC article. Review.
Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.
Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, Sabbagh M, Honig LS, Porsteinsson AP, Ferris S, Reichert M, Ketter N, Nejadnik B, Guenzler V, Miloslavsky M, Wang D, Lu Y, Lull J, Tudor IC, Liu E, Grundman M, Yuen E, Black R, Brashear HR; Bapineuzumab 301 and 302 Clinical Trial Investigators. Salloway S, et al. Among authors: grundman m. N Engl J Med. 2014 Jan 23;370(4):322-33. doi: 10.1056/NEJMoa1304839. N Engl J Med. 2014. PMID: 24450891 Free PMC article. Clinical Trial.
Preclinical and clinical biomarker studies of CT1812: A novel approach to Alzheimer's disease modification.
Izzo NJ, Yuede CM, LaBarbera KM, Limegrover CS, Rehak C, Yurko R, Waybright L, Look G, Rishton G, Safferstein H, Hamby ME, Williams C, Sadlek K, Edwards HM, Davis CS, Grundman M, Schneider LS, DeKosky ST, Chelsky D, Pike I, Henstridge C, Blennow K, Zetterberg H, LeVine H 3rd, Spires-Jones TL, Cirrito JR, Catalano SM. Izzo NJ, et al. Among authors: grundman m. Alzheimers Dement. 2021 Aug;17(8):1365-1382. doi: 10.1002/alz.12302. Epub 2021 Feb 8. Alzheimers Dement. 2021. PMID: 33559354 Free PMC article. Clinical Trial.
Value-Generating Exploratory Trials in Neurodegenerative Dementias.
Friedman LG, McKeehan N, Hara Y, Cummings JL, Matthews DC, Zhu J, Mohs RC, Wang D, Hendrix SB, Quintana M, Schneider LS, Grundman M, Dickson SP, Feldman HH, Jaeger J, Finger EC, Ryan JM, Niehoff D, Dickinson SL, Markowitz JT, Owen M, Travaglia A, Fillit HM. Friedman LG, et al. Among authors: grundman m. Neurology. 2021 May 18;96(20):944-954. doi: 10.1212/WNL.0000000000011774. Epub 2021 Mar 5. Neurology. 2021. PMID: 33674360 Free PMC article. Review.
Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial.
Dam T, Boxer AL, Golbe LI, Höglinger GU, Morris HR, Litvan I, Lang AE, Corvol JC, Aiba I, Grundman M, Yang L, Tidemann-Miller B, Kupferman J, Harper K, Kamisoglu K, Wald MJ, Graham DL, Gedney L, O'Gorman J, Haeberlein SB; PASSPORT Study Group. Dam T, et al. Among authors: grundman m. Nat Med. 2021 Aug;27(8):1451-1457. doi: 10.1038/s41591-021-01455-x. Epub 2021 Aug 12. Nat Med. 2021. PMID: 34385707 Clinical Trial.
NSAIDs and hypertension.
Aisen PS, Schafer K, Grundman M, Thomas R, Thal LJ. Aisen PS, et al. Among authors: grundman m. Arch Intern Med. 2003 May 12;163(9):1115; author reply 1115-6. doi: 10.1001/archinte.163.9.1115-a. Arch Intern Med. 2003. PMID: 12742818 No abstract available.
Biomarkers for Alzheimer's disease therapeutic trials.
Hampel H, Wilcock G, Andrieu S, Aisen P, Blennow K, Broich K, Carrillo M, Fox NC, Frisoni GB, Isaac M, Lovestone S, Nordberg A, Prvulovic D, Sampaio C, Scheltens P, Weiner M, Winblad B, Coley N, Vellas B; Oxford Task Force Group. Hampel H, et al. Prog Neurobiol. 2011 Dec;95(4):579-93. doi: 10.1016/j.pneurobio.2010.11.005. Epub 2010 Dec 2. Prog Neurobiol. 2011. PMID: 21130138 Review.
Antioxidant strategies for Alzheimer's disease.
Grundman M, Grundman M, Delaney P. Grundman M, et al. Proc Nutr Soc. 2002 May;61(2):191-202. doi: 10.1079/PNS2002146. Proc Nutr Soc. 2002. PMID: 12133201 Review.
132 results